OrPhar-SEFH 2024-2027 Strategic Plan

Area of Science:

• * Pharmaceutical Sciences
• * Health Services Research
• * Rare Disease Management

Background:

• * The landscape of rare disease management presents unique challenges for hospital pharmacy.
• * A strategic plan is needed to guide the evolution of hospital pharmacy services in rare diseases.
• * Existing trends and barriers impact both rare disease treatment and hospital pharmacy roles.

Purpose of the Study:

• * To develop the OrPhar-SEFH Strategic Plan 2024-2027 for transforming hospital pharmacy in rare diseases.
• * To identify and prioritize actionable strategies for hospital pharmacists.
• * To enhance patient care, access to orphan drugs, and overall health outcomes.

Main Methods:

• * A multi-phase approach including literature review, interviews (pharmacists, patients), and SWOT analysis.
• * Identification and classification of trends and barriers around four change levers.
• * Grouping of actions into five strategic axes (AEIOU) and prioritization by impact and feasibility.

Main Results:

• * 23 lines of action developed across Alliances, Evidence, Research/Innovation, Optimization, and Union.
• * Key prioritized actions include pharmacist collaboration in orphan drug evaluation, critical evidence analysis, and interdisciplinary team integration.
• * A network of specialized hospital pharmacist services for rare diseases is proposed.

Conclusions:

• * The OrPhar-SEFH Strategic Plan 2024-2027 provides a roadmap for hospital pharmacists in rare diseases.
• * Enhancing the hospital pharmacist's role is crucial for improving orphan drug access, evaluation, and patient care processes.
• * The plan aims to optimize rare disease management, leading to improved patient outcomes and quality of life.